All In Biotech

BLA 761278 · Chiesi Farmaceutici Spa

Lamzede

Velmanase Alfa-Tycv

NovelPriority reviewOrphan

CDER novel approval, Feb 16, 2023: To treat non-central nervous system manifestations of alpha-mannosidosis

Last checked: Nov 20, 2026Latest source record: Feb 16, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Feb 16, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

9

5 Phase 3, 1 recruiting

FAERS reports

56

31 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SEVERE HYPERSENSITIVITY REACTIONS Hypersensitivity Reactions Including Anaphylaxis Patients treated with LAMZEDE have experienced hypersensitivity reactions, including anaphylaxis. Appropriate medical support measures, including cardiopulmonary resuscitation equipment , should be readily available during LAMZEDE administration. If a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue LAMZEDE immediately and initiate appropriate medical treatment. In patients with severe hypersensitivity reaction, a desensitization procedure to LAMZEDE may be considered [see Warnings and Precautions ( 5.1 )]. WARNING: SEVERE HYPERSENSITIVITY REACTIONS See full prescribing information for complete boxed warning. Hypersensitivity Reactions Including Anaphylaxis Appropriate medical support measures, including cardiopulmonary resuscitation equipment , should be readily...

What it is approved for

From the label in effect Feb 21, 2023.

1 INDICA TIONS AND USAGE LAMZEDE is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients. LAMZEDE is recombinant human lysosomal alpha-mannosidase indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients. ( 1 )

Mechanism: Alpha-mannosidosis is a lysosomal storage disease that results from reduced activity of the enzyme alpha-mannosidase, caused by gene variants in Mannosidase Alpha Class 2B Member 1. Alpha-mannosidase catalyzes the degradation of accumulated mannose-containing oligosaccharides. The deficiency of alpha-mannosidase causes an intra-lysosomal accumulation of mannose-rich oligosaccharides in various tissues. Velmanase alfa-tycv provides an exogenous source of alpha-mannosidase. Velmanase alfa-tycv is internalized via binding to the mannose-6-phosphate receptor on the cell surface and transported...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 16, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
  • LAMZEDE · VELMANASE ALFA-TYCV 10MG · POWDER, FOR INJECTION SOLUTION, LYOPHILIZED POWDER, · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Velmanase Alfa" as an intervention, any sponsor and status, largest first.

All 9 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue6
  • product complaint5
  • pyrexia5
  • off label use4
  • product administration interrupted4
  • vomiting4
  • abdominal pain3
  • arthropathy3
  • haemoglobin decreased3
  • infusion related reaction3
  • urticaria3
  • blood creatinine increased2

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20236
202417
202525
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Lamzede (Velmanase Alfa-Tycv) · HCPCS J0217

2024 spending

$2.0M

Beneficiaries

n/a

65 claims

Per beneficiary

n/a

2024 ASP limit $442.00 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$2,049,467

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Chiesi Farmaceutici Spa

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.